NKTR catalyst calendar

NEKTAR THERAPEUTICS

Upcoming catalysts
3
Cash runway
46.3 months
Cash & investments
$684M
Phase 3 programs
9

NEKTAR THERAPEUTICS is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 12, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 46.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 36 concluded trials, 75% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 12, 2026 est. Next quarterly earnings (projected) Earnings —
May 15, 2028 A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis Trial Milestone Phase 3
June 15, 2028 A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis Trial Milestone Phase 3

Track NKTR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open NKTR in the tracker

Recent history

DateEventTypePhase
October 1, 2026 8-K filed: Reg FD disclosure Filing —
September 25, 2026 8-K filed: Other event Filing —
September 8, 2026 8-K filed: Reg FD disclosure Filing —
August 13, 2026 Quarterly results filed (8-K) Earnings —
May 8, 2026 8-K filed: Material agreement, Leadership change Corporate —
May 7, 2026 Quarterly results filed (8-K) Earnings —
April 23, 2026 8-K filed: Material agreement, Other event Corporate —
April 20, 2026 8-K filed: Reg FD disclosure, Other event Filing —
April 20, 2026 8-K filed: Reg FD disclosure Filing —
March 12, 2026 Quarterly results filed (8-K) Earnings —
February 13, 2026 8-K filed: Material agreement, Other event Corporate —
February 10, 2026 8-K filed: Reg FD disclosure, Other event Filing —
February 10, 2026 8-K filed: Reg FD disclosure Filing —
January 27, 2026 8-K filed: Reg FD disclosure Filing —
December 16, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 26, 2025 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) Trial Milestone Phase 2
November 21, 2025 8-K filed: Leadership change Corporate —
November 10, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 6, 2025 Quarterly results filed (8-K) Earnings —
September 18, 2025 8-K filed: Reg FD disclosure, Other event Filing —
August 7, 2025 Quarterly results filed (8-K) Earnings —
July 1, 2025 8-K filed: Material agreement, Other event Corporate —
June 27, 2025 8-K filed: Other event Filing —
June 24, 2025 8-K filed: Reg FD disclosure, Other event Filing —
June 4, 2025 8-K filed: Other event Filing —
May 8, 2025 Quarterly results filed (8-K) Earnings —
May 6, 2025 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis Trial Milestone Phase 2
May 22, 2024 NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma Trial Milestone Phase 2/Phase 3
April 24, 2023 NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma Trial Milestone Phase 1
March 30, 2023 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Trial Milestone Phase 1/Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.